BLOOD PRESSURE LOWERING MECHANISMS OF ANGIOTENSIN CONVERTING ENZYME

血管紧张素转换酶的降血压机制

• 批准号: 6122733
• 负责人: RONALD T SMITH
• 金额: $ 3.88万
• 依托单位: WAKE FOREST UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122733
• 关键词: angiotensins; blood pressure; cardiovascular disorder chemotherapy; clinical research; diabetes mellitus; drug screening /evaluation; enzyme inhibitors; hormone regulation /control mechanism; human subject; human therapy evaluation; hypertension; peptidyl dipeptidase A; prostaglandin E; vasodilators

Past research by members of the Hypertension Center showed Angiotensin (1-7) acts as a vasodilator by stimulation of tissue prostaglandins. Thus, Antiotensin (1-7) might be involved in the hypotensive effect of ACE inhibitors. The goal of this pilot study is to determine whether angiotensin converting enzyme (ACE) inhibition influences vasodioator hormones (ang 1-7) and prostaglandin E2 (PGE2) similarly in diabetic and non-diabetic hypertensives.

高血压中心成员的过去研究表明血管紧张素 （1-7）通过刺激组织前列腺素充当血管扩张剂。 因此， 抗激素（1-7）可能参与ACE的降压作用 抑制剂。这项试验研究的目的是确定是否 血管紧张素转化酶（ACE）抑制会影响血管疾病剂 激素（ANG 1-7）和前列腺素E2（PGE2）在糖尿病和 非糖尿病高血压。